The European Chemicals Agency (ECHA) and authorities from Denmark, Germany, the Netherlands, Norway and Sweden have released a progress update on the process to restrict per- and polyfluoroalkyl substances (PFAS) in Europe.
Helsinki, 20 November 2024 – The five authorities (Dossier Submitters) and ECHA’s scientific committees for Risk Assessment (RAC) and for Socio-Economic Analysis (SEAC) continue to consider more than 5 600 scientific and technical comments received from third parties during the consultation in 2023.
This consultation input helps the Dossier Submitters to progressively update and improve the information on PFAS. It has also helped identify uses that were not specifically named in the initial proposal, and these are being incorporated into existing sector assessments or grouped into new sectors as needed. Examples include sealing applications, technical textiles, printing applications and other medical applications, such as packaging and excipients for pharmaceuticals.
Alternative restriction options, besides a full ban or a ban with time-limited derogations, are also being considered. An alternative option could, for example, involve conditions allowing the continued manufacture, placing on the market or use of PFAS instead of a ban. This consideration is particularly relevant for uses and sectors where evidence suggests that a ban could lead to disproportionate socio-economic impacts. These alternative options are being considered for uses including, but not limited to:
- batteries;
- fuel cells; and
- electrolysers.
The proportionality of each alternative option will be evaluated and compared to the initial two restriction options of a full ban or a ban with time-limited derogations. All this updated information is feeding into ECHA committees’ ongoing evaluation of the proposal.
21-Nov-2024
Read More https://echa.europa.eu/-/echa-and-five-european-countries-issue-progress-update-on-pfas-restriction
#echa #pfas #fda #news #medicaldevice